3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
4
NIH
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
497
Neoplasms
302
Breast Neoplasms
294
Colorectal Neoplasms
228
Neoplasm Metastasis
194
Prostatic Neoplasms
175
Ovarian Neoplasms
173
Lung Neoplasms
159
Multiple Myeloma
158
Recurrence
131
Melanoma
125
Pancreatic Neoplasms
115
Squamous Cell Carcinoma of Head and Neck
104
Stomach Neoplasms
102
Leukemia, Myeloid, Acute
101
Endometrial Neoplasms
101
Small Cell Lung Carcinoma
88
Leukemia, Lymphocytic, Chronic, B-Cell
87
Triple Negative Breast Neoplasms
84
Lymphoma, Non-Hodgkin
84
Carcinoma, Renal Cell
83
Carcinoma, Hepatocellular
79
Urinary Bladder Neoplasms
77
Lymphoma, Large B-Cell, Diffuse
74
Lymphoma, Follicular
68
Advanced Solid Tumors
66
Lymphoma
62
Parkinson Disease 4, Autosomal Dominant Lewy Body
61
Glioblastoma
58
Head and Neck Neoplasms
56
Interventions
durvalumab
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Glandular and Epithelial
×
90 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled
NCT07377487
2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA
Recruiting
51 enrolled